Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker EXEL
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Mary C. Beckerle Director | EXEL Exelixis, Inc. | Sale | 9,812 | $53.66 | $526.5K Sale | Form 4 ↗ |
| Jun 1, 2026 | Jack L. Wyszomierski Director | EXEL Exelixis, Inc. | Sale | 3,925 | $50.55 | $198.4K Sale | Form 4 ↗ |
| Jun 1, 2026 | Sue Gail Eckhardt Director | EXEL Exelixis, Inc. | Sale | 9,812 | $50.14 | $492.0K Sale | Form 4 ↗ |
| May 26, 2026 | Dana Aftab EVP, Research and Development | EXEL Exelixis, Inc. | Sale | 43,451 | $50.35 | $2.2M Sale | Form 4 ↗ |
| May 20, 2026 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 32,110 | $49.81 | $1.6M Sale | Form 4 ↗ |
| May 18, 2026 | Christopher J. Senner EVP and CFO | EXEL Exelixis, Inc. | Sale | 34,901 | $50.00 | $1.7M Sale | Form 4 ↗ |
| May 18, 2026 | Brenda Hefti SVP and General Counsel | EXEL Exelixis, Inc. | Sale | 6,625 | $50.21 | $332.6K Sale | Form 4 ↗ |
| May 7, 2026 | Mary C. Beckerle Director | EXEL Exelixis, Inc. | Sale | 7,712 | $48.45 | $373.6K Sale | Form 4 ↗ |
| May 7, 2026 | Maria C. Freire Director | EXEL Exelixis, Inc. | Sale | 20,634 | $46.00 | $949.2K Sale | Form 4 ↗ |
| May 7, 2026 | George Poste Director | EXEL Exelixis, Inc. | Sale | 60,000 | $45.71 | $2.7M Sale | Form 4 ↗ |
| Feb 24, 2026 | Dana Aftab EVP, Research and Development | EXEL Exelixis, Inc. | Sale | 47,918 | $44.50 | $2.1M Sale | Form 4 ↗ |
| Feb 19, 2026 | Dana Aftab EVP, Research and Development | EXEL Exelixis, Inc. | Sale | 29,873 | $44.35 | $1.3M Sale | Form 4 ↗ |
| Feb 18, 2026 | Jack L. Wyszomierski Director | EXEL Exelixis, Inc. | Sale | 99,574 | $44.01 | $4.4M Sale | Form 4 ↗ |
| Feb 18, 2026 | Julie Smith Director | EXEL Exelixis, Inc. | Sale | 20,030 | $44.30 | $887.3K Sale | Form 4 ↗ |
| Feb 18, 2026 | Julie Smith Director | EXEL Exelixis, Inc. | Sale | 44,087 | $44.50 | $2.0M Sale | Form 4 ↗ |
| Feb 18, 2026 | Brenda Hefti SVP and General Counsel | EXEL Exelixis, Inc. | Sale | 18,669 | $44.01 | $821.6K Sale | Form 4 ↗ |
| Feb 17, 2026 | Julie Smith Director | EXEL Exelixis, Inc. | Sale | 42,422 | $43.33 | $1.8M Sale | Form 4 ↗ |
| Feb 17, 2026 | Christopher J. Senner EVP and CFO | EXEL Exelixis, Inc. | Sale | 30,617 | $43.67 | $1.3M Sale | Form 4 ↗ |
| Feb 17, 2026 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 64,778 | $43.50 | $2.8M Sale | Form 4 ↗ |
| Feb 17, 2026 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 3,036 | $43.84 | $133.1K Sale | Form 4 ↗ |
| Feb 13, 2026 | Christopher J. Senner EVP and CFO | EXEL Exelixis, Inc. | Sale | 34,278 | $43.00 | $1.5M Sale | Form 4 ↗ |
| Feb 13, 2026 | Sue Gail Eckhardt Director | EXEL Exelixis, Inc. | Sale | 3,856 | $43.79 | $168.9K Sale | Form 4 ↗ |
| Feb 13, 2026 | Bob Oliver Director | EXEL Exelixis, Inc. | Sale | 21,162 | $43.90 | $929.0K Sale | Form 4 ↗ |
| Feb 13, 2026 | Bob Oliver Director | EXEL Exelixis, Inc. | Sale | 9,088 | $43.61 | $396.3K Sale | Form 4 ↗ |
| Nov 25, 2025 | Caligan Partners LP Director | EXEL Exelixis, Inc. | Buy | 27,532 | $43.12 | $1.2M Buy | Form 4 ↗ |
| Nov 21, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 28,043 | $42.58 | $1.2M Sale | Form 4 ↗ |
| Nov 20, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 10,648 | $41.77 | $444.8K Sale | Form 4 ↗ |
| Nov 20, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 23,539 | $41.93 | $987.0K Sale | Form 4 ↗ |
| Nov 20, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 10,000 | $42.11 | $421.1K Sale | Form 4 ↗ |
| Nov 12, 2025 | Stelios Papadopoulos Director | EXEL Exelixis, Inc. | Sale | 100,000 | $43.55 | $4.4M Sale | Form 4 ↗ |
| Nov 11, 2025 | Dana Aftab EVP, Research and Development | EXEL Exelixis, Inc. | Sale | 48,383 | $42.50 | $2.1M Sale | Form 4 ↗ |
| Nov 11, 2025 | Mary C. Beckerle Director | EXEL Exelixis, Inc. | Sale | 18,838 | $41.90 | $789.3K Sale | Form 4 ↗ |
| Nov 11, 2025 | Mary C. Beckerle Director | EXEL Exelixis, Inc. | Sale | 5,784 | $42.03 | $243.1K Sale | Form 4 ↗ |
| Jun 3, 2025 | Jack L. Wyszomierski Director | EXEL Exelixis, Inc. | Sale | 7,535 | $43.09 | $324.7K Sale | Form 4 ↗ |
| Jun 2, 2025 | Sue Gail Eckhardt Director | EXEL Exelixis, Inc. | Sale | 4 | $43.67 | $175 Sale | Form 4 ↗ |
| Jun 2, 2025 | Sue Gail Eckhardt Director | EXEL Exelixis, Inc. | Sale | 18,834 | $42.74 | $805.0K Sale | Form 4 ↗ |
| May 21, 2025 | Tomas J. Heyman Director | EXEL Exelixis, Inc. | Sale | 4,544 | $44.29 | $201.3K Sale | Form 4 ↗ |
| May 20, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 34,387 | $44.06 | $1.5M Sale | Form 4 ↗ |
| May 16, 2025 | George Poste Director | EXEL Exelixis, Inc. | Sale | 20,634 | $45.99 | $949.0K Sale | Form 4 ↗ |
| May 16, 2025 | Christopher J. Senner EVP and CFO | EXEL Exelixis, Inc. | Sale | 100,000 | $46.00 | $4.6M Sale | Form 4 ↗ |
| May 16, 2025 | Amy C. Peterson EVP Prod Dev & Med Aff & CMO | EXEL Exelixis, Inc. | Sale | 72,776 | $45.47 | $3.3M Sale | Form 4 ↗ |
| May 15, 2025 | Stelios Papadopoulos Director | EXEL Exelixis, Inc. | Sale | 15,874 | $44.35 | $704.0K Sale | Form 4 ↗ |
| May 15, 2025 | Stelios Papadopoulos Director | EXEL Exelixis, Inc. | Sale | 20,634 | $44.35 | $915.1K Sale | Form 4 ↗ |
| May 15, 2025 | Jeffrey Hessekiel EVP & General Counsel | EXEL Exelixis, Inc. | Sale | 25,000 | $46.18 | $1.2M Sale | Form 4 ↗ |
| May 15, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 116,383 | $48.05 | $5.6M Sale | Form 4 ↗ |
| May 15, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 10,000 | $46.95 | $469.5K Sale | Form 4 ↗ |
| May 14, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 10,000 | $42.68 | $426.8K Sale | Form 4 ↗ |
| May 1, 2025 | Dana Aftab CSO/EVP Disc & Trans Research | EXEL Exelixis, Inc. | Sale | 1,508 | $39.00 | $58.8K Sale | Form 4 ↗ |
| Mar 3, 2025 | Patrick J. Haley EVP, Commercial | EXEL Exelixis, Inc. | Sale | 10,000 | $38.80 | $388.0K Sale | Form 4 ↗ |
| Feb 28, 2025 | Julie Smith Director | EXEL Exelixis, Inc. | Sale | 19,294 | $37.62 | $725.8K Sale | Form 4 ↗ |
Full history on every feed is part of Premium. Premium loads older rows, up to 10,000, and CSV downloads.
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 5:36 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances